IZI Medical Products Announces the Launch of Vertefix® HV Cement with Insite™ Tracking Beads

IZI Medical Products, LLC (“IZI”), a leading manufacturer of interventional radiology devices and products to treat vertebral compression fractures, announces the official launch of Vertefix HV Cement (“Vertefix HV”).

Vertefix HV provides a unique solution that addresses the need for real-time flow visualization during cement injection for vertebroplasty and kyphoplasty procedures.

“Our goal in developing Vertefix HV was to give physicians a better way to track and control where cement is flowing during their procedures,” said Greg Groenke, CEO, IZI Medical Products. “The introduction of variable-sized barium particles with high viscosity makes this possible, improving outcomes and safety for patients.”

“Vertefix HV will help you control your cement and allow you to have excellent cement viscosity immediately after mixing. It has an optimal volume of cement with good working time and viscosity, along with great visualization so you can see when the cement is flowing and where it is going. The Insite beads are a great addition and now novel to all of the cements on the market. Bottom line is it’s the best cement I’ve used since I can remember,” said Dr. Douglas Beall, Chief of Services and Interventional Spine Services, Comprehensive Specialty Care, Edmond, Oklahoma.

“Improved visualization of cement has always been one of the goals to provide better safety with kyphoplasty and vertebroplasty. If you can visualize the cement better it makes the procedure safer, so the improved visualization by having variable-size barium particles is really nice,” said Dr. Jonathan Morris, Neuroradiologist.

The new Vertefix HV Cement with Insite tracking beads offers high viscosity and long working time and is an innovative enhancement to IZI’s vertebral augmentation portfolio. “We worked with physicians to find out what would really help them in vertebral augmentation procedures. Their input was insightful, and we’re pleased with what we’ve been able to deliver with Vertefix HV,” said Jovie Soriano, SVP Marketing and Business Development, IZI Medical Products.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version